IQVIA Holdings (IQV) stock is back in focus after the company agreed a collaboration with Medera to support cardiac gene therapies and human based drug discovery platforms through its global clinical and regulatory infrastructure.

The Medera collaboration sits alongside a series of recent updates from IQVIA Holdings, including raised 2026 revenue guidance, a detailed second quarter earnings release and ongoing share repurchases. It also comes after a 30.06% 90 day share price return and 29.89% 1 year total shareholder return that signal building momentum despite a softer 1 day move and a modest 5 year total shareholder return decline.

If this kind of healthcare AI exposure interests you, it could be worth widening your watchlist to see what else is setting up in 42 healthcare AI stocks.

IQVIA Holdings appears to be a solid business with updated guidance, new partnerships and an active buyback program, and the stock has already moved sharply over the past 90 days. The next step is to consider whether that strength is already reflected in the current price.

Most Popular Narrative: 20% Overvalued

The most followed narrative currently places IQVIA Holdings fair value at $232.00, which sits very close to the last close of $232.43, and uses a detailed set of revenue, margin and earnings assumptions to get there.

Record R&D Solutions backlog and strong sequential increases in qualified pipeline and RFP flow indicate sustained demand for outsourced clinical research, particularly in oncology, cell & gene therapies, and novel therapeutic areas, which should translate into resilient, long-term contracted revenues and improved earnings visibility.

Curious what is baked into that $232.00 fair value for IQVIA Holdings. The narrative leans on steady top line expansion, firmer margins and a punchy future earnings multiple. The real surprise is how these moving parts combine with a single discount rate to justify today’s price band.

Result: Fair Value of $232.00 (OVERVALUED)

However, IQVIA Holdings still faces pressure from CRO pricing and high leverage, which could squeeze margins and limit flexibility if conditions move against current assumptions.

Another View on IQVIA Holdings Valuation

The narrative pricing IQVIA Holdings at a fair value of $232.00 suggests the stock looks about 20% overvalued on those assumptions. Yet our DCF model points the other way. On that framework, IQVIA Holdings trades around 36% below an estimated future cash flow value of $360.77, which implies a very different risk reward profile. Which version of “fair” do you feel more comfortable leaning on?

Next Steps

Seen enough to sense both optimism and concern around IQVIA Holdings? Act while the details are fresh and weigh up the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond IQVIA Holdings?

If IQVIA Holdings has sharpened your focus, do not stop here. Broaden your opportunity set with targeted stock ideas that could suit different parts of your portfolio.

• Target potential mispricings by reviewing companies highlighted in the 50 high quality undervalued stocks.
• Strengthen your income stream by scanning stocks featured in the 9 dividend fortresses.
• Reduce portfolio stress by focusing on companies within the 77 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.